Search Results
Your search for what matches 6083 pages
Showing 601 - 650Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Report Examines Accuracy of ChatGPT in Providing Information on Common Cancer Myths and Misconceptions
In the first study of its kind, researchers evaluated the reliability and accuracy of ChatGPT’s cancer information, as chatbots and artificial intelligence (AI) have become popular resources. A report published by Johnson et al in JNCI Cancer Spectrum summarized the accuracy of the tool in...
ACCC Releases 2022 Impact Report
The Association of Community Cancer Centers (ACCC)—which represents more than 34,000 multidisciplinary oncology practitioners—outlined successful programs and initiatives in 2022 that advanced oncology care, according to the ACCC's 2022 Impact Report. These new programs and initiatives included...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Dan T. Vogl, MD, Comments on Follow-up of the UK NCRI Myeloma XI Trial
Dan T. Vogl, MD, Associate Professor of Medicine at the Hospital of the University of Pennsylvania and Director of the Abramson Cancer Center at the Perelman School of Medicine, Philadelphia, told The ASCO Post that the follow-up of the UK NCRI Myeloma XI trial confirms the importance of...
'Don't Blame the Test'
“There are misconceptions about prostate cancer screening,” Karen Knudsen, MBA, PhD, said in an interview with The ASCO Post about newly published cancer statistics, including an increased incidence of prostate cancer, particularly advanced-stage disease. Dr. Knudsen is Chief Executive Officer of...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Unique Challenges of Cancer Care in India
In this installment of The ASCO Post’s Global Oncology, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Rajendra Toprani, MBBS, MS, MCh, Head of the Department of Head and Neck Surgical Oncology at HCG Cancer Centre, Ahmedabad, India. Dr. Toprani’s areas of interest include oral,...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Radiation Oncology Workforce Expected to Remain Stable Through 2030, According to ASTRO Report
After analyzing the U.S. radiation oncology workforce, investigators projected a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030, according to an American Society for Radiation Oncology (ASTRO) Workforce Taskforce review...
Expert Point of View: Aparna R. Parikh, MD
Aparna R. Parikh, MD, Assistant Professor of Medicine, Harvard Medical School, and Director of the Massachusetts General Hospital Cancer Center’s Global Cancer Care Program, Boston, shared her thoughts on the C-800 study of balstilimab plus botensilimab with The ASCO Post. Noting that the...
Improving Physician-Patient Communication
In 2017, ASCO published a new guideline in the Journal of Clinical Oncology outlining the best practices for communicating effectively with patients and their family members.1 The goal of the communication guideline is to provide oncologists with a framework of specific practices to enable them to...
Understanding the Link Between Prognostic Perception and Patient-Oncologist Prognostic Discordance in the Advanced Cancer Setting
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
Depression May Be Linked to Higher Levels of Inflammation, Poorer Outcomes in Patients With Lung Cancer
Patients with lung cancer who have moderate to severe depression may be two to three times more likely to have inflammation levels that predict poor survival rates, according to a new study published by Andersen et al in PLOS One. The findings may help explain why a substantial portion of patients...
Chemotherapy May Alter Immune Cell Landscape in Patients With Pancreatic Cancer
Chemotherapy may affect the immune system’s ability to attack tumors in patients with pancreatic ductal adenocarcinoma, according to a new study published by Werba et al in Nature Communications. Background Pancreatic ductal adenocarcinoma is hard to detect and treat, with a 5-year survival rate of ...
Studies Focusing on Age- and Race-Related Disparities in Multiple Myeloma and Sickle Cell Disease
Research that addresses the compounding effects of age and race/ethnicity on access to quality health care and patient-centered outcomes such as physical function, frailty, and survival continues to be an emerging area of inquiry in hematology. Accordingly, novel research employing qualitative and...
Black Women at High Risk of Breast Cancer May Face Obstacles in Receiving Preventive Care
Black women at high risk of developing breast cancer may face a variety of obstacles keeping them from receiving preventive care that could increase their chances of survival if they did develop the disease, according to a new study published by Padamsee et al in PLOS One. The new findings provide...
How Patient Navigation Programs Are Helping Drive Equitable Care for Patients With Cancer and Improve Outcomes
Although patient navigation is increasingly recognized as an important component in the delivery of patient-centered cancer care, the service is not universally available across all cancer programs in the United States, often because of the concerns of extra cost without tangible financial...
Hospital Surgical Volume May Impact Survival in Patients With Pancreatic Cancer Whose Minimally Invasive Surgery Is Converted to an Open Procedure
Patients with pancreatic ductal adenocarcinoma whose pancreatoduodenectomy is converted to an open (CTO) procedure from a minimally invasive procedure as a result of complications may fare better at institutions that perform more minimally invasive pancreatic cancer surgeries annually, according to ...
Immunotherapy Costs May Drive Increase in Medicare Spending for Outpatient End-of-Life Cancer Care
Researchers have discovered that recent increases in Medicare spending on outpatient end-of-life cancer care may have been driven almost entirely by costs associated with immunotherapy, which is given to fewer than one in five patients, according to a new study published by Mantz et al in the...
New Study Demonstrates Inferior Vena Cava Filters May Be Safe and Effective Way to Prevent Venous Thromboembolism
Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
Expert Point of View: Pretesh R. Patel, MD
Session co-moderator, Pretesh R. Patel, MD, Associate Professor of Radiation Oncology at Winship Cancer Institute of Emory University, shared his thoughts on the Neo-AEGIS1 findings with The ASCO Post. “I think we continue to have equipoise about chemoradiation and perioperative chemotherapy in...
Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer
A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction cancer has ended in “equipoise,” according to the investigators of the Neo-AEGIS trial. In a study reported at the 2023 ASCO GI Cancers Symposium, perioperative...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Understanding the Health Disparities That Sexual and Gender Minorities Face in Oncology Care
In its programming for the 2022 ASCO Annual Meeting, ASCO included a special Education Session on “Gender-Based and Sexual Orientation Inequities: Promoting Inclusion, Visibility, and Data Accuracy in Oncology.” The session offered a comprehensive discussion on the challenges that sexual and gender ...
Whole-Genome Sequencing May Illuminate the Genetic Evolution of Classical Hodgkin Lymphoma
Researchers have discovered that whole-genome sequencing—rather than the current standard of exome sequencing—may allow physicians to better identify genetic changes that drive cancer development and growth, and create the most effective, personalized treatment plans for patients with classical...
Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma
Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
Grateful to Be Alive
Although there is no history of cancer in my family, I guess it isn’t surprising that I would develop an aggressive form of melanoma on my scalp after years of ultraviolet radiation from sun exposure. Still, getting the diagnosis was devastating. I first noticed a small lump on the top of my head ...
Yale Study Indicates Older Patients Are Excluded From Progress Against Lung Cancer
The widespread use of immune checkpoint inhibitors has led to significant benefits in younger patients with advanced lung cancer; however, older patients have not experienced similar survival benefits, according to research from Yale Cancer Center. The study was published in JAMA Oncology.1 “There ...
Intensified Drug Regimen Added to Standard of Care Improves Outcomes in Subset of Patients With High-Risk Prostate Cancer
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
Emerging Second- and Third-Line Therapies for Unresectable and Metastatic Melanoma
This is Part 4 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss the second- and third-line therapy options for unresectable and metastatic melanoma. The...
Robert A. Brodsky, MD, Begins Term as 2023 ASH President
Robert A. Brodsky, MD, a renowned expert in classical hematology, will serve as President of the American Society of Hematology (ASH) for a year-long term through December 2023. Dr. Brodsky is Professor of Medicine and Oncology and Director of Hematology at Johns Hopkins University School of...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Addition of Venetoclax to Intensive Chemotherapy Yields Durable Responses in Younger Patients With High-Risk AML
Longer follow-up of a phase II study of venetoclax combined with cladribine, idarubicin, and cytarabine (CLIA) as a front-line induction regimen for younger patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) shows a pattern of durable efficacy consistent with...
Expert Point of View: Mikkael Sekeres, MD
“Standard treatment of older or less fit adults with acute myeloid leukemia (AML) is now venetoclax/azacitidine, which has been shown to improve overall survival vs azacitidine monotherapy. Since that backbone was established, there has been a tsunami of trials looking at drugs added to this...
The Beauty and the Beast of Cancer
The most humbling—and fortunate—experience I’ve had since I was diagnosed with osteosarcoma 13 years ago at the age of 43 was being treated in the pediatric wing of a major cancer center in New York City. It is pretty difficult to feel sorry for yourself when you are sitting next to a 14-year-old...
Raised in Africa, Surgeon Kristin Flowers, MD, Continues the Tradition of Service in a Rural Hospital in Alaska
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kristin Flowers, MD, a general surgeon at Tanana Valley Clinic at Fairbanks Memorial Hospital in rural Alaska. Dr. Flowers’ surgical areas of interest include treating...
Traveling the World at an Early Age Gave Perspective and Balance to Future Oncology Leader Derek Raghavan, MD, PhD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Founding President of the Levine Cancer Institute. Established in 2011, the Levine Cancer Institute is part of Atrium Health (formerly the...
Common Immune-Related Adverse Events: Spotlight on Gastrointestinal and Hepatic Toxicities
At the inaugural MD Anderson Clinical Education Symposium on Immunotherapy Organ Toxicity Management (IOTOX), a panel of experts discussed common immune-related adverse events associated with immune checkpoint inhibitor therapy, including gastrointestinal (GI), hepatic, dermatologic, pulmonary, and ...
New JCO Oncology Practice Special Series Highlights Current State of Team-Based Care, Innovations, and Future Direction
What is team-based cancer care, and how has it evolved over the past decade? A special series in ASCO’s JCO Oncology Practice highlights transformations in team-based delivery models within the cancer care system and their potential direction. A carefully curated series of 15 peer-reviewed articles ...
Expert Point of View: Virginia Kaklamani, MD, Lori J. Pierce, MD, FASTRO, FASCO, and Eric Winer, MD, FASCO
Press briefing moderator Virginia Kaklamani, MD, Professor of Medicine at UT Health San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, said the findings from RxPONDER and those regarding the tumor microenvironment of metastasis (TMEM) doorway are ...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
